stem cell news 101019-22

kittybruce

Glance at last issue:
+ {, n+ ^, t# P7 ?9 B  R
1 p0 Y2 Q  K0 H"Three of the authors ... wish to retract this Article after a re-examination of the publication raised serious concerns with some of the reported data. These concerns have undermined the authors' confidence in the support for the scientific conclusions reported."--The retraction of a paper published in January in Nature  states.2 w9 f( e0 {5 j; a" N  Y1 n
6 d8 |, m! C* L% H4 c" s/ [2 d! `
"I regret any confusion that has resulted from the publication of this paper and am deeply grateful to my colleagues who are painstakingly working with me to replicate these experiments and evaluate the data."--Wagers, who is a principal faculty member of the Harvard Stem Cell Institute and an associate professor at Harvard Medical School. " s/ L; B: r2 _# V
; K) `! s) t5 I
"A lot of challenges in stem cell therapy is that the cells convert into tumors. And so with this type of device, we can remove the cells safely and effectively."--UC Irvine scientist Jonathan Lakey.
1 i; r  r, Q5 K/ |- G8 F/ W, P$ u( [  l2 I! K
"The increase in the number of hematopoietic progenitor and stem cells in Sept4-deficient mice brings with it the possibility of accelerating the accumulation of mutations in stem cells. They have more stem cells with enhanced resistance to apoptosis. In the end, that leads to more cells accumulating mutations that cannot be eliminated...The work supports the idea that the stem cell is the seed of the tumor and that the transition from a normal stem cell to a cancer stem cell involves increased resistance to apoptosis."--Research associate Maria Garcia-Fernandez, Hermann Steller, head of the Strang Laboratory of Apoptosis and Cancer Biology of Rockefeller University.
/ a% ~( o' A# E; _' r+ o5 V. b% u
“We’re putting a lot of effort into further refining these products and making a lot of progress with processes for large-scale production of these cells, because that’s really one of the bottlenecks at the moment.”--Peter Sartipy, Ph.D., senior principal scientist at Cellartis.
6 e4 i$ Z6 N% C% |! A
! j8 ?% B' D! o0 t“What we would administer to a patient is a much more typical drug—a small molecule or a biologic—and not the cells themselves. We envision delivering drugs to the patient, whether it’s local administration for formation of new bone in localized areas or systemic in other disease cases. The key to this is knowing that the cells that you’re using for your screens are as closely matched as possible to the endogenous adult stem cells.”--Tom Novak, Ph.D., senior vp of R&D for Fate Therapeutics.7 y# f2 ?# R& L$ k! g
: Z# K9 h! u" ~
“We looked under the premise that all the cells in the dish were identical. It turns out that’s really not the case at all.”--Dr. Mick Bhatia, a lead author of the study and the scientific director at the McMaster Stem Cell and Cancer Research Institute.; I* p' b3 H- J; ^6 s& X
7 c  y) g: X. `$ X4 F" ]% [# ^1 }
"The big challenge with embryonic stem cells is getting all the cells in a culture to do the same thing together, in order to make specific cells types. This work is a big step towards that. Using the same principles we could adapt the procedure to produce not just chondrocytes, but other types of cells, for different clinical applications."--Professor Kimber, Co‐director of NWESCC.
: [  G, q2 H# M) X- |; s
- R6 k2 @2 @- {! Y
5 P# Y) P5 r' T% s9 B' G# K+ `- Z# VThis issue:
4 i7 D% Y2 Q) M" d# x- Q
* \! h0 M# W7 u' a6 C) _$ Z
+ d7 A+ F+ x7 Z- M4 w* g
# p) ]' m6 a! f) r1 b2 O8 IVideo news:' \0 u( P! b% ~- M# P6 D) E

, O& U" [$ I+ ^+ K* Y* SMajor Milestone in Stem Cell Therapy4 @' c! h& M% C) P0 o0 g
http://video.foxnews.com/v/43689 ... -stem-cell-therapy/1 ^  Q: w3 `) m5 z# U

1 T$ B, d3 b' bStem Cell Alternative Found
& |! @" }, z$ \. ehttp://www.redorbit.com/news/vid ... nd/33362/index.html
9 i& c& F7 U" H- s
3 C; `2 G9 _. q0 B4 w1 x3 e' K$ N8 m% NResearchers at UIC have used stem cells to reattach teeth in the jaws of rats0 D% w; @1 c* ?. e# o" [  x
http://news.medill.northwestern.edu/chicago/news.aspx?id=170759! K8 {7 w: b: w
* E7 ?6 x: l- ^5 C; v
Stem Cells: Programming and Personalized Medicine--Rudolf Jaenisch
: R* H0 }4 Q+ w9 whttp://mitworld.mit.edu/video/828

wyl050223

现在有没有人做胚胎干细胞诱导出肿瘤干细胞的，是否能够通过这种方法来研究肿瘤细胞某一支的形成机制？

wanglibin

回复 2# wyl050223
$ X8 V" X% k2 \- S" O
' j5 l  v* a! y$ t+ |: K
! D' t* k/ V  E    请问你这样做的意义何在？肿瘤是由体细胞突变而来的，你这样做怎么去模仿肿瘤干细胞的发生？

wyl050223

回复 3# wanglibin " J, o9 C6 |& r. |8 p

' X: G/ T0 o$ _8 G
7 O! `) a' b5 c5 j7 z# ]# w5 H    我说的是研究机制啊 通过导入不同的质粒或者是通过病毒转染 带有不同的基因 最后比较各个细胞之间的表形 看符合哪一种，因为我刚刚接触干细胞 什么都还不懂 不知可行不 或者说 有哪些理论还有实验已经证实没有价值？谢谢了

wanglibin

回复 4# wyl050223 3 ]) ?* C& k5 [+ B; P9 ~
7 X7 l! g/ p! X4 I+ s0 T! E& c8 ^

9 W* a4 M# k$ n1 M    在比较两种细胞是不是完全相同的问题上，还没有一个统一的标准，如果你用干细胞诱导产生了一种肿瘤干细胞，只在表型上说他们是相同与否是没有说服力的。对于肿瘤发生机制问题我也不懂，你的想法还是挺厉害的。

wyl050223

回复 5# wanglibin
5 j& M$ w+ n" U. B' D1 A4 N$ I
! r) e; U; D0 a+ O
" v0 g+ i( y' @# C" @    好吧 thank you

ydj19830

回复 4# wyl050223
$ s$ T8 t& k2 i  m) h( r; x
( c# w. V' S6 [) u7 w. |' a: }+ u7 a$ t) @' q" N& {8 n) V% {
    其实可以试试，可以仿照IPS诱导的思路，按这条路不是诱导出胰岛B细胞了么...
( y  P0 R7 @5 X8 e7 T2 c. W! \祝你好运！

kittybruce

回复 2# wyl050223 7 l$ }8 V' ~! l" T4 j
/ G2 @; E# t" O( p

9 D; `, }3 T. `3 k0 d    搞ES机制的人不care这个idea，搞ES应用的人fear这个idea，搞肿瘤的人confused with这个idea，你说，这个idea会有人做么？